WO2001085903A2 - A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same - Google Patents
A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same Download PDFInfo
- Publication number
- WO2001085903A2 WO2001085903A2 PCT/CN2001/000590 CN0100590W WO0185903A2 WO 2001085903 A2 WO2001085903 A2 WO 2001085903A2 CN 0100590 W CN0100590 W CN 0100590W WO 0185903 A2 WO0185903 A2 WO 0185903A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- polynucleotide
- p5cr
- sequence
- characteristic sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- the present invention belongs to the field of biotechnology. Specifically, the present invention describes a new polypeptide, a human protein 9 containing a characteristic sequence fragment of P5CR, and a polynucleotide sequence encoding the polypeptide. The invention also relates to a preparation method and application of the polynucleotide and the polypeptide. Background technique
- Proline plays a very important physiological function in the body.
- Proline residues are post-translationally modified to produce 4-hydroxy-L-proline, which is an important component of certain proteins, especially collagen. It is well known that collagen is involved in many biological processes such as maintaining the strength of bone tendons, blood vessels, cartilage, and skin in the body, and is one of the important components in the body.
- ⁇ ⁇ -pyrroline-5-hydroxyreductase catalyzes the last step in the biosynthesis process from glutamic acid to proline in vivo, which is NAD (P) -dependent 1-pyrroline-5-hydroxy oxidation Is proline.
- NAD NAD
- P -dependent 1-pyrroline-5-hydroxy oxidation Is proline.
- the abnormal expression of this enzyme will directly affect the synthesis of proline in the organism, and then affect the synthesis of some relevant important proteins, that is, affect some important physiological processes.
- ⁇ ⁇ -pyrroline-5-hydroxy reductase is widely distributed in the biological world, and it exists in eukaryotes, archaea and eukaryotes.
- the enzyme has a high sequence similarity in these organisms, and the C-terminus of ⁇ -pyrroline-5-hydroxyreductase contains a conserved consensus sequence fragment as follows: [PALF] -X (2, 3)-[LIV] -X (3)-[LIVM]-[STAC]-[STV] -X- [GAN] -GXTX (2)-[AG]-[LIV] -X (2)-[LMF ]-[DENQK]; ⁇ 1-pyrroline-5-hydroxy reductase from all different sources contains this conserved sequence fragment, which may be the active center of the enzyme, and mutations at this site will lead to inactivation of the enzyme Thus, it affects the final synthesis of proline and affects a series of related biological processes.
- This protein is closely related to the
- the human protein 9 protein containing the characteristic sequence fragment of P5CR plays an important role in important functions in the body, and it is believed that a large number of proteins are involved in these regulatory processes. Therefore, identification in the art has been required. More people involved in these processes have protein 9 protein containing P5CR characteristic sequence fragments, especially the amino acid sequence of this protein is identified. Isolation of the protein 9 protein encoding gene containing the characteristic sequence fragment of P5CR in newcomers also provides a basis for research to determine the role of this protein in health and disease states. This protein may form the basis for the development of diagnostic and / or therapeutic drugs for diseases, so it is important to isolate its coding for DM. Disclosure of invention
- Another object of the invention is to provide a polynucleotide encoding the polypeptide.
- Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding a human protein 9 containing a fragment containing a characteristic sequence of P5CR.
- Another object of the present invention is to provide mimic compounds, antagonists, agonists, and inhibitors directed to protein 9 of a polypeptide of the present invention, which contains a P5CR characteristic sequence fragment.
- Another object of the present invention is to provide a method for diagnosing and treating diseases related to abnormalities of human protein 9 containing a characteristic sequence fragment of P5CR.
- the present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof.
- the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
- sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 1188 to 1433 in SEQ ID NO: 1; and (b) a sequence having positions 1 to 3878 in SEQ ID NO: 1 Sequence of bits.
- the present invention further relates to a vector, particularly an expression vector, containing the polynucleotide of the present invention; a host cell genetically engineered with the vector, including a transformed, transduced or transfected host cell; A method of preparing the polypeptide of the present invention by culturing the host cell and recovering the expressed product.
- the invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
- the invention also relates to a method for screening a compound that mimics, activates, antagonizes or inhibits the activity of a protein 9 protein containing a characteristic sequence fragment of P5CR, which comprises utilizing the polypeptide of the invention.
- the invention also relates to compounds obtained by this method.
- the invention also relates to a method for detecting a disease or disease susceptibility related to abnormal expression of protein 9 protein containing human P5CR characteristic sequence fragments in vitro, which comprises detecting mutations in the polypeptide or a polynucleotide sequence encoding the same in a biological sample. Or detecting the amount or biological activity of a polypeptide of the invention in a biological sample.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
- the present invention also relates to the use of the polypeptides and / or polynucleotides of the present invention in the preparation of a medicament for treating cancer, developmental or immune diseases, or other diseases caused by abnormal expression of protein 9 containing human P5CR characteristic sequence fragments. .
- Nucleic acid sequence refers to an oligonucleotide, a nucleotide or a polynucleotide and a fragment or part thereof, and may also refer to a genomic or synthetic DNA or RNA, they can be single-stranded or double-stranded, representing the sense or antisense strand.
- amino acid sequence refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof.
- amino acid sequence in the present invention relates to the amino acid sequence of a naturally occurring protein molecule, such "polypeptide” or “protein” does not mean to limit the amino acid sequence to a complete natural amino acid related to the protein molecule .
- a protein or polynucleotide “variant” refers to an amino acid sequence having one or more amino acids or nucleotide changes or a polynucleotide sequence encoding it. The changes may include deletions, insertions or substitutions of amino acids or nucleotides in the amino acid sequence or nucleotide sequence. Variants can have "conservative" changes in which the substituted amino acid has a structural or chemical property similar to the original amino acid, such as the replacement of isoleucine with leucine. Variants can also have non-conservative changes, such as replacing glycine with tryptophan.
- “Deletion” refers to the deletion of one or more amino acids or nucleotides in an amino acid sequence or nucleotide sequence.
- “Insertion” or “addition” refers to an alteration in the amino acid sequence or nucleotide sequence that results in an increase in one or more amino acids or nucleotides compared to a naturally occurring molecule. "Replacement” refers to the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides.
- Biological activity refers to a protein that has the structure, regulation, or biochemical function of a natural molecule.
- the term “immunologically active” refers to the ability of natural, recombinant, or synthetic proteins and fragments thereof to induce a specific immune response and to bind specific antibodies in a suitable animal or cell.
- An "agonist” refers to a molecule that, when combined with human protein 9 containing a characteristic sequence fragment of P5CR, can cause the protein to change, thereby regulating the activity of the protein.
- An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that binds to human protein 9 containing a P5CR characteristic sequence fragment.
- Antagonist refers to a biological or immunological activity that can block or modulate human protein 9 containing P5CR characteristic sequence fragments when combined with human protein 9 containing P5CR characteristic sequence fragments.
- Molecule Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecule that binds to human protein 9 containing P5CR characteristic sequence fragments.
- Regular refers to a change in the function of human protein 9 containing a characteristic sequence fragment of P5CR, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological properties of human protein 9 containing a characteristic sequence fragment of P5CR. , Functional or immune properties.
- substantially pure ' means substantially free of other proteins, lipids, sugars or other substances with which it is naturally associated.
- Those skilled in the art can use standard protein purification techniques to purify human proteins containing P5CR characteristic sequence fragments.
- a substantially pure human protein 9 containing P5CR characteristic sequence fragments can generate a single main band on a non-reducing polyacrylamide gel.
- the purity of human protein 9 containing characteristic sequence fragments of P5CR can be analyzed by amino acid sequence .
- Complementary refers to the natural binding of a nucleotide by base-pairing under conditions of acceptable salt concentration and temperature.
- sequence "C-T-G-A” can be combined with the complementary sequence "G-A-C-T”.
- the complementarity between two single-stranded molecules may be partial or complete.
- the degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
- “Homology” refers to the degree of complementarity and can be partially homologous or completely homologous.
- Partial homology refers to a partially complementary sequence that at least partially inhibits hybridization of a fully complementary sequence to a target nucleic acid. This inhibition of hybridization can be detected by performing hybridization (Southern blotting or Nor thern blotting, etc.) under conditions of reduced stringency.
- Substantially homologous sequences or hybridization probes can compete and inhibit the binding of completely homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other specifically or selectively.
- Percent identity refers to the percentage of sequences that are identical or similar in the comparison of two or more amino acid or nucleic acid sequences. The percent identity can be determined electronically, such as by the MEGALIGN program (La sergene sof tware package, DNASTAR, Inc., Madi son Wis.). The MEGALIGN program can be Methods such as the Clus ter method compare two or more sequences (Higg ins, DG and PM Sharp (1988) Gene 73: 237-244). 0 The Clus ter method arranges groups of sequences into clusters by checking the distance between all pairs. The clusters are then assigned in pairs or groups. The percent identity between two amino acid sequences such as sequence A and sequence B is calculated by the following formula: The number of matching residues between sequence A and sequence X 100
- the percent identity between nucleic acid sequences can also be determined by the Clus ter method or by a method known in the art such as Jotun He in. (He in J., (1990) Methods in erazumology 183: 625-645) 0
- Similarity refers to the degree of identical or conservative substitutions of amino acid residues at corresponding positions in the alignment of amino acid sequences.
- Amino acids used for conservative substitutions for example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; having an uncharged head group is Similar hydrophilic amino acids may include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.
- Antisense refers to a nucleotide sequence that is complementary to a particular DNA or RNA sequence.
- Antisense strand refers to a nucleic acid strand that is complementary to the “sense strand”.
- Derivative refers to a chemical modification of HFP or a nucleic acid encoding it. Such a chemical modification may be the replacement of a hydrogen atom with an alkyl group, an acyl group or an amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological characteristics of natural molecules.
- Antibody refers to a complete antibody molecule and its fragments, such as Fa,? ( ⁇ ') 2 and?, which can specifically bind to human epitopes of protein 9 containing a characteristic sequence fragment of P5CR.
- a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
- isolated refers to the removal of a substance from its original environment (for example, its natural environment if it occurs naturally).
- a naturally occurring polynucleotide or polypeptide is not isolated when it is present in a living animal, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system.
- Such a polynucleotide may be part of a vector, or such a polynucleotide or polypeptide may be part of a composition. Since the carrier or composition is not part of its natural environment, they are still isolated.
- isolated refers to the separation of a substance from its original environment (if natural Matter, the original environment is the natural environment).
- polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances existing in the natural state. .
- isolated human P5CR characteristic sequence fragment-containing protein 9 refers to human P5CR characteristic sequence fragment-containing protein 9 that is substantially free of other proteins, lipids, sugars, or other substances with which it is naturally associated.
- Those skilled in the art can use standard protein purification techniques to purify human proteins containing P5CR characteristic sequence fragments 9.
- Substantially pure polypeptides can produce a single main band on a non-reducing polyacrylamide gel.
- the purity of the human protein 9 polypeptide containing the characteristic sequence fragment of P5CR can be analyzed by amino acid sequence.
- the present invention provides a new polypeptide, a human protein 9 containing a characteristic sequence fragment of P5CR, which basically consists of the amino acid sequence shown in SEQ ID NO: 2.
- the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide.
- the polypeptides of the present invention can be naturally purified products or chemically synthesized products, or can be produced from prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells) using recombinant techniques.
- polypeptide of the invention may be glycosylated, or it may be non-glycosylated.
- the polypeptides of the invention may also include or exclude the initial methionine residue.
- the invention also includes fragments, derivatives and analogs of human protein 9 containing fragments characteristic of the P5CR sequence.
- fragment refers to a polypeptide that substantially maintains the same biological function or activity of the human P5CR characteristic sequence-containing fragment 9 of the present invention.
- a fragment, derivative, or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
- the amino acid may or may not be encoded by a genetic codon; or ( ⁇ ) such a type in which a group on one or more amino acid residues is substituted by another group to include a substituent; or (III) such A type in which a mature polypeptide is fused to another compound (such as a compound that extends the half-life of a polypeptide, such as polyethylene glycol); or (IV) a type of polypeptide sequence in which an additional amino acid sequence is fused into a mature polypeptide (such as the leader sequence or secreted sequence or the sequence used to purify this polypeptide or protease sequence)
- an additional amino acid sequence is fused into a mature polypeptide (such as the leader sequence or secreted sequence or the sequence used to purify
- the present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- the polynucleotide sequence of the present invention includes the nucleotide sequence of SEQ ID NO: 1.
- the polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a polynucleotide sequence of 3878 bases in length and its open reading frame (1188-1433) encodes 81 amino acids.
- This polypeptide has the characteristic sequence of P5CR. It can be deduced that the human protein 9 containing the characteristic sequence fragment of P5CR has the structure and function represented by P5CR.
- the polynucleotide of the present invention may be in the form of DNA or RM.
- DNA forms include cDNA, genomic DNA, or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- DNA can be coding or non-coding.
- the coding region sequence encoding the mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
- a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
- the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
- polynucleotide encoding a polypeptide refers to a polynucleotide that includes the polypeptide and a polynucleotide that includes additional coding and / or non-coding sequences.
- the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
- This polynucleotide variant can be a naturally occurring allelic variant or a non-naturally occurring variant.
- These nucleotide variants include substitution variants, deletion variants, and insertion variants.
- an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
- the invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity between the two sequences).
- the present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions.
- "strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1 ° /.
- hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
- nucleic acid fragments that hybridize to the sequences described above.
- a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding human protein 9 containing P5CR characteristic sequence fragments.
- polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
- the specific polynucleotide sequence of the present invention encoding human protein 9 containing a characteristic sequence fragment of P5CR can be obtained by various methods.
- polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) Hybridization of genomic or cDNA libraries with probes to detect homologous polynucleotide sequences Columns, and 2) antibody screening of expression libraries to detect cloned polynucleotide fragments having common structural characteristics.
- the DNA fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DNA of the polypeptide.
- genomic DNA isolation is the least commonly used. Direct chemical synthesis of DM sequences is often the method of choice.
- the more commonly used method is the isolation of cDNA sequences.
- the standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library.
- the construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
- Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
- genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (l) DNA-DNA or DNA-RNA hybridization; (2) the presence or absence of marker gene functions; (3) determination of human transcripts of protein 9 containing P5CR characteristic sequence fragments Level; (4) detecting protein products of gene expression by immunological techniques or measuring biological activity. The above methods can be used singly or in combination.
- the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides.
- the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
- the probe used here is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention.
- the genes or fragments of the present invention can of course be used as probes.
- DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
- the protein product of human protein 9 gene containing P5CR characteristic sequence fragments can be detected by immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA).
- immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA).
- a method using PCR technology to amplify DNA / RNA is preferably used to obtain the gene of the present invention.
- the RACE method RACE-Rapid Amplification of cDNA Ends
- the primers used for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein. Select and synthesize using conventional methods.
- the amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.
- polynucleotide sequence of the gene of the present invention or various DM fragments and the like obtained as described above can be determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, sequencing must be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
- the present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell produced by genetic engineering using the vector of the present invention or directly using a human protein 9 coding sequence containing a characteristic sequence fragment of P5CR, and recombinant technology to produce the Said method of polypeptide.
- a polynucleotide sequence encoding a human protein 9 containing a characteristic sequence fragment of P5CR can be inserted into a vector to constitute a recombinant vector containing the polynucleotide of the present invention.
- vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art.
- Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors (Rosenberg, et al.
- any plasmid and vector can be used to construct a recombinant expression vector.
- An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.
- Methods known to those skilled in the art can be used to construct expression vectors containing a DNA sequence encoding a human protein 9 fragment containing a characteristic sequence of P5CR and suitable transcription / translation regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Mo l ecu l ar C l on i ng, a Labora tory Manua l, co ld Spr ing Harbor Labora tory. New York, 1989).
- the DNA sequence can be operably linked to an appropriate promoter in the expression vector to guide mRNA synthesis. Representative examples of these promoters are: the l ac or trp promoter of E.
- the expression vector also includes a ribosome binding site for translation initiation and a transcription terminator. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Examples include 100 to 270 base pairs of SV40 enhancer at a later stage of the replication initiation point, polyoma enhancer and adenovirus enhancer at the late side of the replication initiation point.
- the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance for eukaryotic cell culture. And green fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.
- selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance for eukaryotic cell culture.
- GFP green fluorescent protein
- tetracycline or ampicillin resistance for E. coli.
- a polynucleotide encoding human protein 9 containing a characteristic sequence fragment of P5CR or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to form a genetic engineering containing the polynucleotide or the recombinant vector.
- Host cell refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
- coli Streptomyces
- bacterial cells such as Salmonella typhimurium
- fungal cells such as yeast
- plant cells insect cells
- fly S 2 or Sf 9 animal cells
- animal cells such as CH0, COS or Bowes s melanoma cells Wait.
- Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art.
- the host is a prokaryote such as E. coli
- competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the 0.1 (12 ) method. The steps used are well known in the art.
- MgC l 2 If necessary, transformation can also be performed by electroporation.
- the host is a eukaryote, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and lipids. Body packaging, etc.
- the polynucleotide sequence of the present invention can be used to express or produce recombinant human P5CR-containing characteristic sequence fragment protein 9 (Scence, 1984; 224: 1431). Generally speaking, there are the following steps:
- the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
- a suitable method such as temperature conversion or chemical induction
- the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell.
- recombinant proteins can be isolated and purified by various separation methods using their physical, chemical, and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high Performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- conventional renaturation treatment protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high Performance liquid chromat
- FIG. 1 is a comparison diagram of the amino acid sequence homology of 78 amino acids from 2-79 in the protein 9 containing the characteristic sequence fragment of the P5CR of the present inventors and the characteristic domain of the P5CR.
- the upper sequence is human protein 9 containing the characteristic sequence fragment of P5CR, and the lower sequence is the characteristic domain of P5CR.
- Identical amino acids are represented by single-character amino acids between the two sequences, and similar amino acids are represented by "+”.
- Figure 2 shows the polyacrylamide gel electrophoresis of human protein 9 containing P5CR characteristic sequence fragments.
- Total human fetal brain RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform.
- Poly (A) mRNA was isolated from total RNA using Quik mRNA Isolat ion Kit (product of Qiegene). 2ug poly (A) mRNA is reverse transcribed to form cDNA.
- the Smar t cDNA cloning kit (purchased from CI on tech) was used to insert the 00 fragment into the multiple cloning site of pBSK (+) vector (Clontech) to transform DH5a. The bacteria formed a cDNA library.
- Dye terminate cycle reaction ion sequencing kit product of Perkin-Elmer
- ABI 377 automatic sequencer Perkin-Elmer
- the determined cDNA sequence was compared with the existing public DNA sequence database (Genebank), and it was found that the cDNA sequence of one of the clones 1007hl 0 was new DNA.
- a series of primers were synthesized to determine the inserted cDNA fragments of the clone in both directions.
- the sequence of the human protein 5 containing the characteristic sequence fragment of P5CR of the present invention and the protein sequence encoded by the same were subjected to a profile scan program (Basiclocal Alignment search tool) in GCG [Altschul, SF et al. J. Mol. Biol. 1990 215: 403-10], performing domain analysis in databases such as prosite.
- the human 9 containing the characteristic sequence fragment of P5CR of the present invention is homologous to the domain P5CR from 2-79.
- the homology result is shown in Fig. 1.
- the homology rate is 0.07, the score is 3.69; the threshold value is 3.50.
- Example 3 Cloning of a gene encoding human P5CR-containing characteristic sequence fragment 9 by RT-PCR
- CDNA was synthesized using fetal brain total RNA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification:
- Primerl 5-GGAGAAGGAGCCAATAAAGAAAAA-3 '(SEQ ID NO: 3)
- Primer 2 5 '-GCATGGTAAAGGAATTATTGAGGG- 3' (SEQ ID NO: 4)
- Primerl is a forward sequence located at the 5th end of SEQ ID NO: 1, starting at lbp;
- Primer2 is the 3 'end reverse sequence in SEQ ID NO: 1.
- CI (pH8.5), 1.5mmol / L MgCl 2 , 200 ⁇ mol / L dNTP, lOpmol primer, 1U Taq DNA polymerase (C 1 out ech company product).
- the reaction was performed on a PE9600 DNA thermal cycler (Perkinn Elmer Co., Ltd.) under the following conditions for 25 cycles: 94 ° C 30sec; 55 ° C 30sec; 72 ° C 2min 0 Simultaneously set ⁇ -during RT-PCR Act in is a positive control and template blank is a negative control.
- the amplified product was purified using a QIAGEN kit and ligated to a pCR vector (Invitrogen product) using a TA cloning kit.
- Example 4 Analysis of expression of human protein 9 gene containing P5CR characteristic sequence fragments by Northern blot method: Total RM extraction in one step [Anal. Biochem 1987, 162, 156-159] 0
- This method includes acid guanidinium thiocyanate -Chloroform extraction. That is, the tissue is homogenized with 4M guanidinium isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0), and 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1 ), Mix and centrifuge.
- RNA precipitate Aspirate the aqueous layer, add isopropanol (0.8 vol) and centrifuge the mixture to obtain RNA precipitate. The obtained RM precipitate was washed with 70% ethanol, dried and dissolved in water. Using 20 ⁇ ⁇ RNA, electrophoresis was performed on a 1.2% agarose gel containing 20 mM 3- (N-morpholino) propanesulfonic acid (pH 7.0)-5 mM sodium acetate-1 EDTA-2.2M formaldehyde. It was then transferred to a nitrocellulose membrane. Preparation 32 P- DNA probe labeled with a- 32 P dATP by random priming method.
- the DNA probe used was the sequence of the protein 9 coding region (1188 bp to 1433 bp) of the human P5CR-containing characteristic sequence fragment amplified by PCR shown in FIG. 1.
- Transfer the 32P-labeled probe (approximately 2 x 10 6 cpm / mi) with RNA-nitrocellulose membrane was hybridized overnight at 42 ° C in a solution containing 50% formamide- 25 mM ⁇ 2 PO 4 ( ⁇ 7 ⁇ 4)-5 x SSC- 5 x Denhardt, s solution and 200 g / ml salmon sperm DNA. After hybridization, the filter was washed in 1 x SSC-0.1% SDS at 55 ° C for 30 min. Then, Phosphor Imager was used for analysis and quantification.
- Example 5 In vitro expression, isolation and purification of recombinant human protein 9 containing a characteristic sequence fragment of P5CR
- Priraer3 5-CATGCTAGCATGGTATCTTCAGCTCTGACATCT-3 '(Seq ID No: 5)
- Primer4 5'-CCCGAATTCCTAACTGTATACAGAACTAAAAGG-3' (Seq ID No: 6)
- These two primers contain Nhel and EcoRI digestion sites at the 5 'ends, respectively.
- the coding sequences of the 5 'and 3' ends of the gene of interest are respectively followed by the Nhel and EcoRI restriction sites corresponding to the selective endonuclease sites on the expression vector plasmid pET28b (+) (Novagen, Cat. No. 69865.3). point.
- the pBS-1007hl0 plasmid containing the full-length target gene was used as a template for the PCR reaction.
- the PCR reaction conditions are as follows: a total volume of 50 ⁇ l contains 10 pg of pBS-1007hl0 plasmid, primers Primer-3 and Primer- 4 points; j is lpmol, Advantage polymerase Mix (Clontech) 1 ⁇ 1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68 ° C 2 min, a total of 25 cycles. Nhel and EcoRI were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase.
- Ligation products were transformed by the calcium chloride method Escherichia bacteria DH5CC, overnight (final concentration of 30 ⁇ ⁇ / ⁇ ⁇ 1) LB plates, screened by colony PCR positive clones containing kanamycin method, and sequenced. A positive clone (pET-1007hlO) with the correct sequence was selected, and the recombinant plasmid was transformed into E. coli BL21 (DE3) plySs (product of Novagen) using the calcium chloride method.
- the host bacteria BL21 (pET-1007hl0) was cultured at 37 ° C to the logarithmic growth phase, and IPTG was added to the final concentration lmraol / L, Continue incubation for 5 hours. The bacteria were collected by centrifugation, and the supernatant was collected by centrifugation. The supernatant was collected by centrifugation. The affinity chromatography column His. Bind Quick Cartridge (product of Novagen) was used to obtain 6 histidine (6His-Tag). The purified protein 9 containing P5CR characteristic sequence fragment was purified.
- a peptide 9-specific peptide containing human P5CR characteristic sequence fragments was synthesized using a peptide synthesizer (product of PE company): NH2- et-Val-Ser-Ser-Ala-Leu-Thr-Ser-Leu-Leu-Asn-Arg-Arg-Pro-Asn- C00H (SEQ ID NO: 7).
- the polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex, respectively.
- Suitable oligonucleotide fragments selected from the polynucleotides of the present invention are used as hybridization probes in a variety of ways.
- the probes can be used to hybridize to genomic or cDNA libraries of normal tissue or pathological tissue from different sources to It is determined whether it contains the polynucleotide sequence of the present invention and a homologous polynucleotide sequence is detected.
- the probe can be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissue or pathology. Whether the expression in tissue cells is abnormal.
- the purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by a filter hybridization method.
- Filter hybridization methods include dot blotting, Southern imprinting, Northern blotting, and copying methods. They all use the same steps to immobilize the polynucleotide sample to be tested on the filter.
- the sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer to saturate the non-specific binding site of the sample on the filter with the carrier and the synthesized polymer.
- the pre-hybridization solution is then replaced with a hybridization buffer containing labeled probes and incubated to hybridize the probes to the target nucleic acid.
- the unhybridized probes are removed by a series of membrane washing steps.
- This embodiment uses higher-intensity washing conditions (such as lower salt concentration and higher temperature), so that the hybridization background is reduced and only strong specific signals are retained.
- the probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention
- the polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment.
- the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained.
- oligonucleotide fragment selected from the polynucleotide SEQ ID NO: 1 of the present invention for use as a hybridization probe shall be Following the following principles and several aspects to consider:
- the preferred range of probe size is 18-50 nucleotides
- Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other unknown genomic sequences and their complements The regions are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used;
- Probe 1 which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt):
- Probe 2 which belongs to the second type of probe, is equivalent to the replacement mutation sequence (41Nt) of the gene fragment or its complementary fragment of SEQ ID NO: 1:
- PBS phosphate buffered saline
- step 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
- NC membranes nitrocellulose membranes
- Two NC membranes are required for each probe for subsequent experiments.
- the film is washed with high-strength conditions and strength conditions, respectively.
- the 32 P-Probe (the second peak is free ⁇ - 32P -dATP) is prepared.
- the sample membrane was placed in a plastic bag, and 3-10 mg of prehybridization solution (10xDenhardt's; 6xSSC, 0. lrag / ml was added)
- probe 1 can be used to qualitatively and quantitatively analyze the presence and differential expression of the polynucleotide of the present invention in different tissues.
- polypeptides of the present invention can be directly used in the treatment of diseases, for example, they can treat malignant tumors, adrenal deficiency, skin diseases, various types of inflammation, HIV infection, and immune diseases. '
- Proline plays a very important physiological function in the body. Proline residues are modified after translation to produce 4-hydroxy-L-proline, which is an important component of certain proteins, especially collagen. Collagen is involved in many biological processes such as maintaining the strength of bone tendons, blood vessels, cartilage, and skin in the body, and is one of the important components in the body.
- ⁇ ⁇ -Pyrroline-5-hydroxyreductase (P5CR) catalyzes the last step in the biosynthesis process from glutamic acid to proline in the organism. The abnormal expression of this enzyme will directly affect the synthesis of proline in the organism, and then affect the synthesis of some relevant important proteins, that is, affect some important physiological processes.
- the characteristic sequence of the delta-pyrrololine-5-hydroxyreductase protein family is necessary to form its biological activity.
- the polypeptide of the present invention is a polypeptide containing a characteristic sequence of this protein family. Abnormal expression will lead to abnormal biosynthesis of proline, and then affect the synthesis of certain proteins, especially collagen, and affect bone tendons, blood vessels, cartilage and The function of tissues and organs such as the skin and related diseases.
- the abnormal expression of the protein 9 containing the characteristic sequence fragment of P5CR of the present invention will produce various diseases, especially glutamate metabolism disease, connective tissue disease, various tumors, developmental disorders, inflammation, and immunity.
- Diseases including but not limited to:
- Connective tissue diseases rheumatic fever, systemic lupus erythematosus, dermatomyositis, polymyositis, sclerosis, mixed connective tissue disease, panniculitis, sarcoidosis, vasculitis, purine metabolic disease, gout
- Tumors of various tissues gastric cancer, liver cancer, breast cancer, leukemia, lymphoma, thyroid tumor, uterine fibroids, neurofibromas, colon cancer, melanoma, bladder cancer, endometrial cancer, colon cancer, laryngeal cancer, trachea Tumor, fibroid, fibrosarcoma
- developmental disorders congenital abortion, cleft palate, limb loss, limb differentiation disorder, atrial septal defect, neural tube defect, congenital hydrocephalus, congenital glaucoma or cataract, mental retardation, brain development disorder, skin, fat and Muscular dysplasia, bone and joint dysplasia, various metabolic defects, sexual retardation
- Inflammation chronic active hepatitis, sarcoidosis, polymyositis, chronic rhinitis, chronic gastritis, cerebrospinal multiple sclerosis, glomerulonephritis, myocarditis, cardiomyopathy, atherosclerosis, gastric ulcer, cervicitis, Various infectious inflammations
- Immune diseases Systemic lupus erythematosus, rheumatoid arthritis, bronchial asthma, urticaria, specific dermatitis, post-infection myocarditis, scleroderma, myasthenia gravis, Guillain-Barre syndrome, common variable immunodeficiency disease , Primary B-lymphocyte immunodeficiency disease, Acquired immunodeficiency syndrome
- the abnormal expression of the protein 9 containing the characteristic sequence fragment of P5CR of the present invention will also produce certain hereditary, hematological diseases and the like.
- the polypeptide of the present invention and the antagonists, agonists and inhibitors of the polypeptide can be directly used in the treatment of diseases, for example, it can treat various diseases, especially glutamate metabolism diseases, connective tissue diseases, various tumors, and development disorders. , Inflammation, immune diseases, certain hereditary, blood diseases, etc.
- the invention also provides methods for screening compounds to identify agents that enhance (agonist) or suppress (antagonist) human protein 9 containing P5CR characteristic sequence fragments.
- Agonists increase human proteins containing P5CR characteristic sequence fragments to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
- a mammalian cell or a membrane preparation expressing human P5CR characteristic sequence fragment-containing protein 9 can be cultured with the labeled human P5CR characteristic sequence fragment-containing protein 9 in the presence of a drug. The ability of the drug to increase or block this interaction is then determined.
- Antagonists of human protein 9 containing a characteristic sequence fragment of P5CR include antibodies, compounds, receptor deletions, and the like that have been screened. Antagonists of human protein 9 containing a characteristic sequence fragment of P5CR can bind to human protein 9 containing a characteristic sequence fragment of P5CR and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide such that The polypeptide cannot perform biological functions.
- human protein 9 containing a characteristic sequence fragment of P5CR can be added to a bioanalytical assay, and by determining the compound's interaction with human protein 5 containing a characteristic sequence fragment of P5CR and its receptor, Influence to determine if a compound is an antagonist.
- Receptor deletions and analogs that act as antagonists can be screened in the same manner as described above for screening compounds.
- Polypeptide molecules capable of binding to human protein 9 containing a characteristic sequence fragment of P5CR can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. During screening, generally, 9 molecules of human proteins containing P5CR characteristic sequence fragments should be labeled.
- the present invention provides a method for producing an antibody using a polypeptide, a fragment, a derivative, an analog thereof, or a cell thereof as an antigen.
- These antibodies can be polyclonal or monoclonal antibodies.
- the present invention also provides an antibody against a human protein 9 epitope containing a P 5 CR characteristic sequence fragment.
- These antibodies include (but Not limited to): polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments produced by Fab expression libraries.
- Polyclonal antibodies can be produced by directly injecting humans containing protein P5CR characteristic sequence fragment 9 into immunized animals (such as rabbits, mice, rats, etc.).
- immunized animals such as rabbits, mice, rats, etc.
- adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant, etc.
- Techniques for preparing a human monoclonal antibody containing protein 9 fragment characteristic of the P5CR sequence include, but are not limited to, hybridoma technology (Kohler and Miste in. Nature, 1975, 256: 495-497), triple tumor technology, human B-cell hybridoma technology, EBV-hybridoma technology, etc.
- Chimeric antibodies that bind human constant regions to non-human variable regions can be produced using known techniques (Morrison et al, PNAS, 1985, 81: 6851).
- the existing technology for producing single chain antibodies U.S. Pat No. 4946778, can also be used to produce single chain antibodies against human protein 9 containing P5CR characteristic sequence fragments.
- Antibodies against protein 9 containing P5CR characteristic sequence fragments can be used in immunohistochemical techniques to detect human protein 5 containing P5CR characteristic sequence fragments in biopsy specimens.
- Monoclonal antibodies that bind to human protein 9 containing a characteristic sequence fragment of P5CR can also be labeled with radioisotopes and injected into the body to track their location and distribution.
- This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
- Antibodies can also be used to design immunotoxins that target a particular part of the body.
- humans containing high-affinity monoclonal antibodies to the P5CR characteristic sequence fragments can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
- a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
- This hybrid antibody can be used to kill human proteins containing P5CR characteristic sequence fragments. 9 positive cells.
- the antibodies of the present invention can be used to treat or prevent diseases related to human protein 9 containing P5CR characteristic sequence fragments. Administration of an appropriate dose of the antibody can stimulate or block the production or activity of human protein 9 containing a P5CR characteristic sequence fragment.
- the present invention also relates to a diagnostic test method for quantitatively and locally detecting the level of protein 9 containing a characteristic sequence fragment of P5CR.
- tests are well known in the art and include FISH assays and radioimmunoassays.
- the level of protein 9 of human P5CR characteristic sequence fragments detected in the test can be used to explain the importance of human P5CR characteristic sequence fragment-containing protein 9 in various diseases and to diagnose human P5CR characteristic sequence fragments Protein 9 plays a role in the disease.
- polypeptide of the present invention can also be used for peptide mapping analysis.
- the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
- Polynucleotides encoding human protein 9 with a characteristic sequence fragment of P5CR can also be used for a variety of therapeutic purposes of.
- Gene therapy technology can be used to treat abnormal cell proliferation, development, or metabolism caused by the non-expression or abnormal / inactive expression of protein 9 containing human P5CR characteristic sequence fragments.
- Recombinant gene therapy vectors (such as viral vectors) can be designed to express mutated human P5CR characteristic sequence fragment protein 9 to inhibit endogenous human P5CR characteristic sequence fragment protein 9 activity.
- a mutated human P5CR characteristic sequence-containing protein 9 may be a shortened human P5CR characteristic sequence-containing protein 9 lacking a signaling domain, although it can bind to downstream substrates, but lacks Signaling activity.
- the recombinant gene therapy vector can be used for treating diseases caused by abnormal expression or activity of protein 9 of the characteristic sequence fragment of P5CR in humans.
- Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus and the like can be used to transfer a polynucleotide encoding human protein 9 containing a characteristic sequence fragment of P5CR into a cell.
- a method for constructing a recombinant viral vector carrying a polynucleotide encoding a human protein 9 fragment containing a characteristic sequence of P5CR can be found in the existing literature (Sambrook, et al.).
- a recombinant polynucleotide encoding human protein 9 containing a characteristic sequence fragment of P5CR can be packaged into liposomes and transferred into cells.
- Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.
- a vector such as a virus, phage, or plasmid
- Oligonucleotides including antisense RNA and DNA
- ribozymes that inhibit human protein 9 mRM containing P5CR characteristic sequence fragments are also within the scope of the present invention.
- a ribozyme is an enzyme-like RNA molecule that can specifically decompose a specific RM. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation.
- Antisense RNA, DNA, and ribozymes can be obtained by any existing RNA or DNA synthesis technology, such as the technology for the synthesis of oligonucleotides by solid-phase phosphate amide chemical synthesis, which is widely used.
- Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA. This DNA sequence has been integrated downstream of the vector's RNA polymerase promoter. In order to increase the stability of the nucleic acid molecule, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the phosphorothioate or peptide bond instead of the phosphodiester bond is used for the ribonucleoside linkage.
- the polynucleotide encoding human protein 9 containing a characteristic sequence fragment of P5CR can be used for the diagnosis of diseases related to human protein 9 containing a characteristic sequence fragment of P5CR.
- Polynucleotides encoding human P5CR characteristic sequence fragments containing protein 9 can be used to detect the expression of human P5CR characteristic sequence fragments containing protein 9 or human disease containing P5CR characteristic sequence fragments of abnormal expression of human 9 .
- a DNA sequence encoding human protein 9 containing a characteristic sequence fragment of P5CR can be used to hybridize a biopsy specimen to determine the expression status of human protein 5 containing a characteristic sequence fragment of P5CR.
- Hybridization techniques include Southern blotting, Nor thern blotting, in situ hybridization, and the like. These technical methods are all mature technologies that are publicly available. Obtained from commercial sources. Part or all of the polynucleotides of the present invention can be immobilized on a microarray as probes
- RNA-polymerase chain reaction in vitro amplification of human protein 9 specific primers containing P5CR characteristic sequence fragments can also be used to detect human protein 5 containing P5CR characteristic sequence fragments.
- Detecting mutations in the protein 9 gene containing human P5CR characteristic sequence fragments can also be used to diagnose human protein 9 containing P5CR characteristic sequence fragments related diseases.
- the form of human protein 9 mutations containing P5CR characteristic sequence fragments includes point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type human P5CR characteristic sequence containing protein 9 DNA sequences. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, the mutation may affect the expression of the protein. Therefore, the Nor thern mark method and Western blot method can be used to indirectly determine whether the gene is mutated.
- the sequences of the invention are also valuable for chromosome identification.
- the sequence specifically targets a specific position on a human chromosome and can hybridize to it.
- specific sites for each gene on the chromosome need to be identified.
- only a few chromosome markers based on actual sequence data are available for marking chromosome positions.
- an important first step is to locate these DNA sequences on a chromosome.
- PCR primers (preferably 15-35bp) are prepared based on cDNA, and the sequences can be located on chromosomes. These primers were then used for PCR screening of somatic hybrid cells containing individual human chromosomes. Only those heterozygous cells containing the human gene corresponding to the primer will produce amplified fragments.
- PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
- oligonucleotide primers of the present invention in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
- Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
- Fluorescent in situ hybridization of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
- FISH Fluorescent in situ hybridization
- the physical location of the sequence on the chromosome can be correlated with the genetic map data. These data can be found in, for example, V. Mckusick, Mendel i an Inher i tance in Man (available online with Johns Hopkins University Welch Medical Library). Linkage analysis can then be used to determine the relationship between genes and diseases that have been mapped to chromosomal regions. Next, the differences in cDNA or genomic sequences between the affected and unaffected individuals need to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease.
- Comparing affected and unaffected individuals usually involves first looking for structural changes in the chromosome, such as deletions or translocations that are visible at the chromosomal level or detectable using cDNA sequence-based PCR.
- the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
- the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
- suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
- the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
- the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
- a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
- these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
- the polypeptides of the invention can be used in combination with other therapeutic compounds.
- the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
- Human protein 9 containing P5CR characteristic sequence fragments is administered in an amount effective to treat and / or prevent a specific indication.
- the amount and range of protein 9 containing P5CR characteristic sequence fragments in a human being administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70433/01A AU7043301A (en) | 2000-04-27 | 2001-04-23 | A novel polypeptide, a human protein 9 containing a fragment of p5cr specific sequence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00115482 CN1320635A (zh) | 2000-04-27 | 2000-04-27 | 一种新的多肽——人含p5cr特征性序列片段的蛋白9和编码这种多肽的多核苷酸 |
CN00115482.6 | 2000-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085903A2 true WO2001085903A2 (en) | 2001-11-15 |
WO2001085903A3 WO2001085903A3 (fr) | 2002-02-28 |
Family
ID=4584928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/000590 WO2001085903A2 (en) | 2000-04-27 | 2001-04-23 | A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1320635A (zh) |
AU (1) | AU7043301A (zh) |
WO (1) | WO2001085903A2 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101838308B1 (ko) * | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
CN111529694A (zh) * | 2020-05-11 | 2020-08-14 | 昆明医科大学第一附属医院 | 人吡咯林-5-羧酸还原酶作为制备治疗皮肤创伤药物的应用 |
-
2000
- 2000-04-27 CN CN 00115482 patent/CN1320635A/zh active Pending
-
2001
- 2001-04-23 AU AU70433/01A patent/AU7043301A/en not_active Abandoned
- 2001-04-23 WO PCT/CN2001/000590 patent/WO2001085903A2/zh active Application Filing
Non-Patent Citations (4)
Title |
---|
GENE vol. 172, no. 1, 1996, pages 149 - 153 * |
J. BIOL. CHEM. vol. 271, no. 16, 1996, pages 9795 - 9800 * |
MOL. GEN. GENET. vol. 221, no. 3, 1990, pages 299 - 305 * |
NUCLEIC ACIDS RES. vol. 10, no. 23, 1982, pages 7701 - 7714 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001085903A3 (fr) | 2002-02-28 |
CN1320635A (zh) | 2001-11-07 |
AU7043301A (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002026973A1 (fr) | Nouveau polypeptide, une ribonucleoproteine nucleaire heterogene humaine 32.01, et un polynucleotide codant ce polypeptide | |
WO2002026972A1 (fr) | Nouveau polypeptide, proteine humaine 20.13 de liaison de l'acide polyadenylique, et polynucleotide codant ce polypeptide | |
WO2001090169A1 (fr) | Nouveau polypeptide, antigene nucleaire de proliferation cellulaire (pcna) 13, et polynucleotide codant ce polypeptide | |
WO2001085903A2 (en) | A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same | |
WO2001083780A1 (fr) | Nouveau polypeptide, methylthioadenosine phosphorylase humaine 37, et polynucleotide codant pour ce polypeptide | |
WO2001055404A1 (fr) | Nouveau polypeptide, alcool deshydrogenase humaine 39, et polynucleotide codant pour ce polypeptide | |
WO2001038540A1 (fr) | Nouveau polypeptide, la methionyl arnt synthetase humaine de 29 kda, et polynucleotide codant pour ledit polypeptide | |
WO2002012296A1 (fr) | Nouveau polypeptide, leucotriene b412-hydroxy deshydrogenase 36 nadp-dependante, et polynucleotide codant ce polypeptide | |
WO2002002611A1 (fr) | Nouveaux polypeptides, domaine de repetition 12 de recepteurs peptidiques de la motilite du sperme et proteine ribosomale l22, et polynucleotides codant ces polypeptides | |
WO2001046240A1 (fr) | Nouveau polypeptide, mariner transposase 19 humaine, et polynucleotide codant pour ce polypeptide | |
WO2001066707A1 (fr) | Nouveau polypeptide, serine protease humaine atp-dependante 11, et polynucleotide codant pour ce polypeptide | |
WO2001055412A1 (fr) | Nouveau polypeptide, phosphoenolpyruvate carboxylase 81, et polynucleotide codant pour ce polypeptide | |
WO2001094591A1 (fr) | Nouveau polypeptide, glyceraldehyde-3-phosphate deshydrogenase 10, et polynucleotide codant ce polypeptide | |
WO2002020606A1 (fr) | Nouveau polypeptide, la proteine humaine 38.39 liee aux defauts d'audition, et polynucleotide codant pour elle | |
WO2001072790A1 (fr) | Nouveau polypeptide, proteine humaine p40 12 de facteur l1, et polynucleotide codant pour ce polypeptide | |
WO2002033077A1 (fr) | Nouveau polypeptide, une proteine de regulation 10.01 etant associee au developpement humain et polynucleotide la codant | |
WO2001075085A1 (fr) | Nouveau polypeptide, serine hydrolase humaine atp-dependante 11.3, et polynucleotide codant pour ce polypeptide | |
WO2001064733A1 (fr) | Nouveau polypeptide, facteur humain 22 lie a la transcription inverse, et polynucleotide codant pour ce polypeptide | |
WO2001087953A1 (fr) | Nouveau polypeptide, galactokinase humaine 11, et polynucleotide codant ce polypeptide | |
WO2002012305A1 (fr) | Nouveau polypeptide, avidine 9, et polynucleotide codant ce polypeptide | |
WO2001081381A1 (fr) | Nouveau polypeptide, proteine humaine 9 contenant un fragment de sequence particulier d'une recombinase specifique au site, et polynucleotide codant pour ce polypeptide | |
WO2001047988A1 (fr) | Nouveau polypeptide, proteine de reparation 11 de l'adn, et polynucleotide codant pour ce polypeptide | |
WO2001055422A1 (fr) | Nouveau polypeptide, proteine 47 de transport de sucre, et polynucleotide codant pour ce polypeptide | |
WO2001083776A1 (fr) | Nouveau polypeptide, hormone de croissance humaine 11, et polynucleotide codant pour ce polypeptide | |
WO2002012494A1 (fr) | Nouveau polypeptide, proteine receptrice de sperme 12, et polynucleotide codant ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |